126 related articles for article (PubMed ID: 26517640)
21. SOX2 and ALDH1 as Predictors of Operable Breast Cancer.
Shima H; Kutomi G; Satomi F; Maeda H; Hirohashi Y; Hasegawa T; Mori M; Torigoe T; Takemasa I
Anticancer Res; 2016 Jun; 36(6):2945-53. PubMed ID: 27272809
[TBL] [Abstract][Full Text] [Related]
22. Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer.
Tolonen TT; Tammela TL; Kujala PM; Tuominen VJ; Isola JJ; Visakorpi T
BJU Int; 2011 Nov; 108(9):1430-8. PubMed ID: 21592298
[TBL] [Abstract][Full Text] [Related]
23. Aldehyde dehydrogenase 1 expression in inflammatory breast cancer as measured by immunohistochemical staining.
Gong Y; Wang J; Huo L; Wei W; Ueno NT; Woodward WA
Clin Breast Cancer; 2014 Jun; 14(3):e81-8. PubMed ID: 24461456
[TBL] [Abstract][Full Text] [Related]
24. The utility of STAT6 and ALDH1 expression in the differential diagnosis of solitary fibrous tumor versus prostate-specific stromal neoplasms.
Guner G; Bishop JA; Bezerra SM; Taheri D; Zahavi DJ; Mendoza Rodriguez MA; Sharma R; Epstein JI; Netto GJ
Hum Pathol; 2016 Aug; 54():184-8. PubMed ID: 27068523
[TBL] [Abstract][Full Text] [Related]
25. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results.
van Gils MP; Hessels D; Hulsbergen-van de Kaa CA; Witjes JA; Jansen CF; Mulders PF; Rittenhouse HG; Schalken JA
Prostate; 2008 Aug; 68(11):1215-22. PubMed ID: 18500693
[TBL] [Abstract][Full Text] [Related]
26. Malignant rhabdoid tumors express stem cell factors, which relate to the expression of EZH2 and Id proteins.
Venneti S; Le P; Martinez D; Xie SX; Sullivan LM; Rorke-Adams LB; Pawel B; Judkins AR
Am J Surg Pathol; 2011 Oct; 35(10):1463-72. PubMed ID: 21921784
[TBL] [Abstract][Full Text] [Related]
27. TWIST1 and SNAI1 as markers of poor prognosis in human colorectal cancer are associated with the expression of ALDH1 and TGF-β1.
Kim YH; Kim G; Kwon CI; Kim JW; Park PW; Hahm KB
Oncol Rep; 2014 Mar; 31(3):1380-8. PubMed ID: 24402192
[TBL] [Abstract][Full Text] [Related]
28. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
29. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.
Matsukawa Y; Semba S; Kato H; Ito A; Yanagihara K; Yokozaki H
Cancer Sci; 2006 Jun; 97(6):484-91. PubMed ID: 16734726
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
31. Role of co-expression of c-Myc, EZH2 and p27 in prognosis of prostate cancer patients after surgery.
Li K; Chen MK; Situ J; Huang WT; Su ZL; He D; Gao X
Chin Med J (Engl); 2013 Jan; 126(1):82-7. PubMed ID: 23286483
[TBL] [Abstract][Full Text] [Related]
32. Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms.
Abdalkader L; Oka T; Takata K; Sato H; Murakami I; Otte AP; Yoshino T
Pathology; 2016 Aug; 48(5):467-82. PubMed ID: 27311868
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Significance of CD44v6, CD133, CD166, and ALDH1 Expression in Small Intestinal Adenocarcinoma.
Eom DW; Hong SM; Kim G; Bae YK; Jang KT; Yu E
Appl Immunohistochem Mol Morphol; 2015; 23(10):682-8. PubMed ID: 25710579
[TBL] [Abstract][Full Text] [Related]
35. Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer.
Ohi Y; Umekita Y; Yoshioka T; Souda M; Rai Y; Sagara Y; Sagara Y; Sagara Y; Tanimoto A
Histopathology; 2011 Oct; 59(4):776-80. PubMed ID: 22014057
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical evaluation of stem cell markers and signal transducer and activator of transcription 6 (STAT6) in solitary fibrous tumors.
Wang C; Qi Y; Liu R; Lan J; Zhou Y; Ju X; Chen D; Zou H; Li S; Hu J; Zhao J; Shen Y; Sun Z; Pang L; Li F
Int J Clin Exp Pathol; 2015; 8(9):10585-94. PubMed ID: 26617768
[TBL] [Abstract][Full Text] [Related]
37. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
38. Identification of musashi-1 and ALDH1 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma.
Liu DC; Yang ZL; Jiang S
Cancer Biomark; 2010-2011; 8(3):113-21. PubMed ID: 22012766
[TBL] [Abstract][Full Text] [Related]
39. Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes.
Roudi R; Korourian A; Shariftabrizi A; Madjd Z
Cancer Invest; 2015; 33(7):294-302. PubMed ID: 26046383
[TBL] [Abstract][Full Text] [Related]
40. ALDH1 expression indicates chemotherapy resistance and poor outcome in node-negative rectal cancer.
Avoranta ST; Korkeila EA; Ristamäki RH; Syrjänen KJ; Carpén OM; Pyrhönen SO; Sundström JT
Hum Pathol; 2013 Jun; 44(6):966-74. PubMed ID: 23332924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
